Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]
In development [GID-TAG508] Expected publication date: TBC
Search results
494 results
-
-
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
In development [GID-TA10018] Expected publication date: TBC
-
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]
In development [GID-TA10033] Expected publication date: TBC
-
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
In development [GID-TA10099] Expected publication date: TBC
-
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
In development [GID-TA10289] Expected publication date: TBC
-
Kidney transplantation (rejection) - belatacept [ID87]
In development [GID-TAG239] Expected publication date: TBC
-
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]
In development [GID-TA10143] Expected publication date: TBC
-
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
In development [GID-TA10261] Expected publication date: TBC
-
Binimetinib for treating melanoma [ID833]
In development [GID-TA10074] Expected publication date: TBC
-
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
In development [GID-TA10081] Expected publication date: TBC
-
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
In development [GID-TA10088] Expected publication date: 27 December 2017
-
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
In development [GID-TA10087] Expected publication date: 27 December 2017
-
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
In development [GID-TA10070] Expected publication date: TBC
-
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]
In development [GID-TAG526] Expected publication date: TBC
-
Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]
In development [GID-TA10045] Expected publication date: TBC
-
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
In development [GID-TA10165] Expected publication date: TBC
-
Masitinib for treating amyotrophic lateral sclerosis [ID967]
In development [GID-TA10157] Expected publication date: TBC
-
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
In development [GID-TA10242] Expected publication date: TBC
-
Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]
In development [GID-TA10047] Expected publication date: TBC
-
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
In development [GID-TAG278] Expected publication date: TBC
-
Mastocytosis (systemic) - masitinib [ID781]
In development [GID-TA10019] Expected publication date: TBC
-
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
In development [GID-TA10180] Expected publication date: TBC
-
Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]
In development [GID-TA10109] Expected publication date: TBC
-
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]
In development [GID-TA10228] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]
In development [GID-TA10110] Expected publication date: TBC
-
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
In development [GID-TA10164] Expected publication date: TBC
-
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
In development [GID-TA10065] Expected publication date: TBC
-
Osteoporosis (postmenopausal women) - abaloparatide [ID882]
In development [GID-TA10071] Expected publication date: TBC
-
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
In development [GID-TAG479] Expected publication date: TBC
-
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]
In development [GID-TA10171] Expected publication date: TBC
-
Peramivir for treating influenza [ID828]
In development [GID-TA10155] Expected publication date: TBC
-
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
In development [GID-TA10177] Expected publication date: TBC
-
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
In development [GID-TA10159] Expected publication date: TBC
-
Lenalidomide for untreated follicular lymphoma ID1245
In development [GID-TA10308] Expected publication date: TBC
-
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
In development [GID-TA10353] Expected publication date: TBC
-
Constipation (opioid induced) - methylnaltrexone bromide [ID700]
In development [GID-TA10003] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]
In development [GID-TA10008] Expected publication date: TBC
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
In development [GID-TA10236] Expected publication date: TBC
-
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]
In development [GID-TA10028] Expected publication date: TBC
-
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487
In development [GID-TA10437] Expected publication date: TBC
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
In development [GID-TA10338] Expected publication date: TBC
-
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
In development [GID-TA10151] Expected publication date: TBC
-
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]
In development [GID-TA10154] Expected publication date: TBC
-
Renal cell carcinoma - sunitinib [ID1076]
In development [GID-TA10166] Expected publication date: TBC
-
Osteoarthritis - diacerein [ID332]
In development [GID-TAG250] Expected publication date: TBC
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
In development [GID-TA10394] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC